Physician profile
Kayvan Amini
NPI 1124243563
$5,588.13
in general payments reported to CMS, 2019-2025
18 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $54.21 · 2021: $283 · 2022: $84.63 · 2023: $377 · 2024: $4,175 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,790 · Food and Beverage: $1,278 · Travel and Lodging: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,790.00 |
| Food and Beverage | $1,277.52 |
| Travel and Lodging | $777.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,162.38 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $260.50 | 2019-2024 | |
| Gilead Sciences, INC. | $204.51 | 2019-2025 | Descovy |
| Janssen Pharmaceuticals, INC | $203.73 | 2019-2023 | Xarelto |
| Pfizer INC. | $171.30 | 2019-2025 | |
| Amgen INC. | $167.35 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $82.33 | 2019-2021 | |
| Cvrx, INC. | $66.21 | 2023-2025 | Barostim Neo System |
| Boston Scientific Corporation | $50.44 | 2021-2025 | General - Therapies |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2023 | Jardiance |
| Heartflow, INC. | $31.66 | 2024 | |
| Baxter Healthcare | $29.02 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $26.95 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.50 | 2024 | Lifevest |
| Amarin Pharma, INC. | $22.92 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $18.47 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.97 | 2023 | Inpefa |
| Regeneron Pharmaceuticals, INC. | $16.07 | 2024 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayvan Amini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.